top of page

Ongoing Clinical Trials in
Focal segmental glomerulosclerosis (FSGS)

Inaxaplin

People with homozygosity or compound heterozygosity for G1 and G2 risk alleles are at high risk of developing multiple kidney diseases...

Sparsentan

Sparsentan is a novel single-molecule dual endothelin (ET-1) and angiotensin receptor antagonist with hemodynamic and anti-inflammatory...

Metformin

Metfromin (MF) which is the most commonly used antidiabetic medications has been found to activate the AMP-activated protein...

Baricitinib:
JUSTICE trial

Baricitinib inhibits Janus kinase (JAK) enzymes, which are intracellular enzymes involved in stimulating hematopoiesis and immune cell...

BI 764198

Familial FSGS has been associated with gain-of-function variants of the transient receptor potential cation channel, subfamily C...

DMX-200
(Repagermanium)

Repagermanium is a C-C chemokine receptor type 2 (CCR2) inhibitor that, when administered concurrently with an angiotensin II receptor...

Multiple Targets for Novel Therapy in FSGS

FSGS.Novel ttargets pdf.jpg

List of Updated Clinical Trials for
Focal segmental glomerulosclerosis (FSGS)

bottom of page